rational
use
interferon
ifn
treatment
multipl
sclerosi
ms
base
recogn
antivir
irnmunomodul
action
pathogenesi
ms
believ
due
immunolog
respons
genet
predispos
individu
local
within
central
nervou
system
white
matter
trigger
exposur
environment
agent
viru
base
person
experi
find
efficaci
ifn
therapi
hamper
ms
patient
presenc
interferon
inhibitor
factor
iif
patient
sera
isol
character
plasmapheresi
pp
done
ms
patient
intermitt
administr
ifna
human
leukocyt
ifn
mark
increas
ifn
patient
modest
increas
three
patient
correl
clinic
improv
three
clinic
nonrespond
show
increas
ifn
level
follow
therapi
abil
remov
iif
lymphokin
inhibitor
factor
lif
pp
may
explain
success
treatment
patient
describ
evalu
helper
cell
suppressor
cell
hladr
antigen
natur
killer
cell
monocyteimacrophag
cell
popul
flow
cytometri
pp
signific
increas
immunecompet
cell
correl
mark
improv
kurtzk
disabl
statu
scale
patient
eight
stabil
patient
show
progress
diseas
either
show
decreas
chang
paramet
therapi
encourag
result
pilot
studi
suggest
pp
combin
immunomodulatori
regimen
ifn
may
effect
therapi
ms
selfrecognit
critic
underpin
normal
function
immun
system
antigenspecif
tlymphocyt
activ
role
major
histocompat
complex
mhc
process
understood
cascad
membran
cytoplasm
nuclear
event
result
recognit
appreci
limit
fashion
antigen
present
mhc
gene
product
recogn
simultan
antigenprocess
cell
specif
tcell
receptor
dual
recognit
necessari
gener
tcell
immun
respons
present
evid
suggest
selfregul
accomplish
manner
process
antigen
bound
mhc
gene
product
posit
neg
control
tcell
receptor
present
antigen
present
suppressor
tlymphocyt
cell
type
associ
mhc
class
gene
product
mani
cell
activ
directli
cytotox
antibodi
recogn
tertiari
surfac
structur
molecul
requir
complement
activ
k
effector
cell
achiev
cell
lysi
cytotox
cell
attach
membran
receptor
calciumindepend
step
releas
proteolyt
enzym
induc
cell
lysi
associ
increas
cytokin
product
lymphocyt
activ
cytokin
depend
protein
kinas
c
also
activ
initi
cell
prolifer
express
mhc
gene
product
interleukin
produc
activ
sustain
respons
serv
distribut
receptor
cytosol
membran
permit
expans
process
interferon
similarli
associ
enhanc
express
mhc
class
gene
product
act
synergi
interferona
interferona
contrast
downregul
bcell
antibodi
synthesi
enhanc
cytotox
cell
express
lo
protein
kinas
c
product
bypass
growth
factor
continu
mitogen
stimulu
activ
gene
sequenc
lead
clonal
expans
involv
cell
octreid
block
process
final
lysi
target
cell
whatev
mean
often
releas
inflammatori
mediat
especi
arachidon
acid
metabolit
majj
trigger
complement
pathway
activ
cytotox
cell
perpetu
process
receptor
downregul
cytokin
occur
continu
exposur
continu
therapeut
plasmapheresi
pp
effect
mean
remov
host
humor
factor
circul
pp
therapi
ms
util
sinc
first
propos
decad
ago
rational
treat
ms
patient
pp
base
assumpt
ms
autoimmun
disord
pp
effect
mean
remov
antibodi
protein
circul
thu
base
current
knowledg
immunopathogenesi
ms
design
immunomodulatori
approach
bring
clinic
improv
patient
progress
ms
unrespons
prior
convent
therapi
total
patient
femal
male
age
rang
year
clinic
definit
ms
fail
previou
therapi
gave
inform
consent
particip
studi
chronic
progress
cours
continu
worsen
strength
visual
chang
ataxia
least
month
serial
neurolog
examin
tabl
initi
followup
evalu
carri
neurologist
use
kurtzk
disabl
statu
scale
kdss
magnet
reson
imag
mri
perform
patient
plaqu
typic
ms
identifi
confirm
radiologist
neurologist
reduc
cost
test
repeat
respond
regularli
repeat
patient
progress
patient
hospit
begin
treatment
initi
necessari
test
patient
receiv
drug
therapi
summar
tabl
pp
mlkg
bodi
weight
patient
plasma
exchang
albumin
normal
salin
contain
meq
meq
meq
kl
plasma
separ
continu
flow
membran
filtrat
devic
cobe
rate
mlmin
pp
done
consecut
day
repeat
everi
day
x
interferon
ifn
interferon
inhibitor
factor
iif
level
check
pp
puls
therapi
schedul
ifn
use
combin
two
type
ifn
combin
octreid
initi
base
clinic
studi
two
type
ifn
recombin
ifna
human
leukocyt
ifn
natur
product
contain
type
ifn
system
administr
clearli
exert
effect
within
central
nervou
system
averag
durat
treatment
patient
receiv
year
except
show
stabilizatiodprogress
follow
pp
patient
receiv
lowdos
cyclophosphamid
mg
iv
x
day
methylprednisolon
mg
iv
x
day
intraven
immunoglobulin
mg
iv
day
mg
iv
day
also
repeat
day
x
month
averag
durat
treatment
patient
year
except
show
stabilizationprogress
cell
line
human
amnion
wish
cell
obtain
american
type
cultur
collect
atcc
grown
eagl
basal
medium
gibco
fb
viru
vesicular
assay
standard
ifn
concentr
show
cytopath
effect
inhibit
dilut
vsv
x
lo
wish
cell
measur
calcul
predetermin
concentr
standard
ifn
x
lo
wish
cellswel
ad
patient
sera
collect
pp
dilut
incub
hour
dilut
vsv
ad
plate
incub
co
waterjacket
incub
plate
check
period
invert
nikon
tm
microscop
desir
cytopath
effect
cpe
viral
control
cpe
refer
achiev
take
approxim
hour
plate
stain
neutral
red
dye
elut
read
microtit
bio
rad
plate
reader
nm
previous
describ
detail
result
report
intern
unitdml
level
iif
sera
ms
patient
calcul
determin
percent
inhibit
protect
wish
cell
standard
ifn
cpe
vsv
elev
cpe
indic
level
iif
present
serum
activ
lymphocyt
subset
interleukin
first
measur
facscan
stain
mixtur
pbl
incub
patient
sera
lif
level
calcul
determin
percent
inhibit
activ
hladr
cell
isol
peripher
blood
lymphocyt
mononuclear
cell
isol
ficollhypaqu
gradient
centrifug
collect
asept
wash
twice
pb
flow
cytometri
stain
flow
cytometri
analysi
perform
describ
facscan
becton
dickinson
serial
use
twocolor
analysi
gate
hladr
nk
surfac
marker
set
cell
stain
fluoresc
andor
phycoerythrin
dye
measur
twentyfour
ms
patient
femal
male
becom
progress
wors
convent
therapi
methyl
prednisolon
enter
studi
inhibitor
factor
ifn
lymphokin
demonstr
circul
time
protocol
entri
patient
diplopia
mark
seven
blur
vision
three
upper
extrem
paralysi
four
lower
extrem
paralysi
two
paraparesi
lower
extrem
note
six
other
difficulti
walk
present
remaind
six
patient
bladder
bowel
dysfunct
sever
diseas
evalu
kurtzk
dss
one
patient
kurtzk
level
three
four
two
one
four
four
four
one
kdss
level
calcul
averag
degre
kurtzk
averag
age
year
averag
durat
diseas
year
year
tabl
patient
low
serum
ifn
high
serum
iif
level
prior
initi
therapi
follow
pp
administr
ifn
methylprednisolon
cyclophosphamid
octreid
immunoglobulin
period
consecut
month
tabl
ii
level
detect
ifn
increas
six
patient
iu
three
patient
iu
ten
patient
iu
two
patient
iu
patient
fig
correl
improv
kurtzk
dss
step
well
stabil
three
patient
continu
worsen
chang
serum
ifn
level
percent
iif
elev
time
first
pp
data
shown
decreas
neglig
level
fourth
pp
eight
patient
patient
chang
three
patient
chang
iif
signific
impact
patient
clinic
statu
five
patient
show
improv
kurtzk
dss
eight
patient
improv
step
eight
stabil
durat
respons
five
patient
improv
year
eight
patient
show
improv
year
eight
patient
stabil
year
none
patient
group
relaps
tabl
chang
number
dimens
ms
plaqu
observ
mri
fact
decreas
dimens
peracut
plaqu
observ
patient
probabl
attribut
regress
periplaqu
edema
data
shown
patient
receiv
four
cours
treatment
common
respond
dramat
fall
circul
iif
andor
lymphokin
inhibitor
level
mean
fall
immun
stimul
evid
respond
normal
circul
immun
complex
patient
elev
count
patient
hladr
nk
serum
ifn
monocyt
macrophag
cell
popul
increas
respond
patient
five
patient
improv
step
kurtzk
cell
therapi
mean
percent
valu
helper
cell
therapi
chang
two
patient
three
patient
becam
three
patient
progress
due
diseas
helper
cell
valu
less
patient
show
improv
kurtzk
rang
hladr
antigen
three
patient
progress
hladr
antigen
pat
respons
patient
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tx
tern
result
also
seen
popul
nk
cell
popul
tabl
iv
hypotens
pp
note
patient
readili
correct
hydrat
fever
develop
hour
ifn
inject
last
hour
rel
well
toler
advers
effect
follow
ifna
administr
progress
toward
effect
treatment
ms
slow
immunolog
studi
suggest
hyperact
defect
immun
respons
patient
ms
experiment
treatment
regimen
design
either
suppress
enhanc
immun
respons
attempt
pp
conjunct
immunosuppress
drug
may
effect
therapi
ms
studi
highdos
intraven
cyclophosphamid
plasma
exchang
acth
suggest
intens
immunosllppress
regimen
effect
halt
progress
diseas
month
doubleblind
control
studi
show
pp
significantli
p
effect
delay
progress
diseas
patient
chronic
progress
multipl
sclerosi
take
immunosuppress
drug
also
canadian
trial
month
assess
patient
show
stabil
improv
greater
pp
group
group
pp
work
ms
entir
clear
rational
pp
ms
includ
chang
tcell
regul
presenc
immunoglobulin
cerebrospin
fluid
profound
lymphocyt
infiltr
activ
ms
lesion
studi
show
first
time
correl
improv
serum
ifn
level
follow
remov
circul
iif
pp
ms
patient
increas
serum
ifn
level
correl
clinic
improv
group
patient
kdss
improv
five
patient
kdss
improv
eight
patient
show
increas
cell
popul
well
hladr
antigenbear
cell
therebi
indic
increas
express
mhc
class
molecul
macrophag
surfac
activ
molecul
result
releas
sever
cytokin
circul
immunomodul
agent
administ
conjunct
pp
use
alter
lymphocyt
expans
cyclophosphamid
diminish
lymphocyt
expans
cerebrospin
fluid
immunoglobulin
synthesi
product
arachidon
acid
metabolit
methylprednisolon
block
fcdepend
bind
antibodyco
cell
immunoglobulin
though
possibl
sort
effect
drug
cours
ms
variou
immunolog
studi
present
feel
pp
play
role
improv
ms
patient
studi
indic
valid
find
